SLC5A2 and diabetes mellitus: Novel treatment options for diabetes mellitus, such as sodium-glucose cotransporter 2 (SGLT-2) inhibitors and glucagon-like peptide 1 receptor (GLP-1) agonists, that have been shown to have cardio and renoprotective effects in non-transplant patients [8], may have an important role to play in the treatment of patients following kidney transplantation.